Janssen's Single-Agent DARZALEX & #174; (daratumumab) Approved by European Commission for Treatment of Multiple Myeloma (MM)

The European Medicines Agency (EMA) has recommended granting a conditional marketing authorisation for Darzalex (daratumumab) for the treatment of adults with relapsed and refractory multiple myeloma. Darzalex is to be used in patients whose previous treatment included a proteasome inhibitor and an immunomodulatory agent (other types of cancer medicines) and whose disease worsened after treatment.
Source: International Myeloma Foundation - Category: Hematology Source Type: news